Calgary, Alberta, December 29, 2023 – Hemostemix Inc. (“Hemostemix” or the “Company”) (TSXV: HEM; OTC: HMTXF) (FSE:2VF0) is pleased to clarify its press release of October 3, 2023. It refered to the private placement of
Latest news and articles!
Calgary, Alberta, October 23, 2023: – Hemostemix Inc. (TSXV:HEM) (OTCQB:HMTXF) (FSE:2VF0) is pleased to announce it has amended its $2.5 million 5 year convertible debenture, which originally closed on June 11, 2021 (“CD1”) resulting in
Calgary, Alberta, October 3, 2023: – Hemostemix Inc. (TSXV:HEM) (OTCQB:HMTXF) (FSE:2VF0) is pleased to announce it closed its private placement of $320,125, the sale of approximately 2.66 Million Units priced at $0.12 each. Each Unit
Calgary, Alberta, September 28, 2023: – Hemostemix Inc. (TSXV:HEM) (OTCQB:HMTXF) (FSE:2VF0) is pleased to announce a new private placement of $325,125, the sale of approximately 2.7 Million Units priced at $0.12 each. Each Unit shall
Calgary, Alberta, September 12, 2023: – Hemostemix Inc. (TSXV:HEM) (OTCQB:HMTXF) (FSE:2VF0) is pleased to announce its study of NCP-01 supporting brain computer interfaces has been submitted for peer review publication. Mitigating Challenges Facing Clinical Applications
Calgary, Alberta, August 29, 2023: – Hemostemix Inc. (TSXV:HEM) (OTCQB:HMTXF) (FSE:2VF0) is pleased to announce it incorporated Hemostemix Quebec Inc. and has applied for grant funding of $6 Million, to locate production of ACP-01 in
Calgary, Alberta, August 14, 2023: – Hemostemix Inc. (TSXV:HEM) (OTCQB:HMTXF) (FSE:2VF0) is pleased to announce that on August 10, 2023 it received a final cost award from the International Center for Dispute Resolution (ICDR), International
Stem cells, the remarkable building blocks of life, possess the unique ability to develop into various specialized cell types in the body, making them crucial for growth, tissue repair, and regeneration. There are two sources
Calgary, Alberta, June 28, 2023: – Hemostemix Inc. (TSXV:HEM) (OTCQB:HMTXF) (FSE:2VF0) is pleased to announce it has closed the sale of 3,362,833 Units at a subscription price of $0.12 per Unit for gross proceeds of
Calgary, Alberta, June 21, 2023: – Hemostemix Inc. (TSXV:HEM) (OTCQB:HMTXF) (FSE:2VF0) is pleased to announce the gross proceeds from the non-brokered private placement are to commence the buildout of production of ACP-01 via a contract